You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. COCRYSTAL PHARMA INC

Cocrystal Pharma Inc XNAS: COCP

Cocrystal Pharma Inc Live Share Price Today, Share Analysis and Chart

Download real time

1.48 0.05 (3.50%)

54.60% Fall from 52W High

12,764 XNAS Volume

XNAS 28 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Cocrystal Pharma Inc Key Metrics

Default

Market Capitalization

Low in industry
15.1

PE TTM

Negative PE TTM
-0.8

PEG TTM

High in industry
0.2

Price to Book

Below industry Median
1.2

Institutional holding current Qtr %

Low in industry
7

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-18.6

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-3.8

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-57

ROE Annual %

Negative ROE Annual %
-54.5

RoA Annual %

Negative RoA Annual %
-49.9
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
9.7 / 100
Momentum Score
Technically Bearish
29.4 / 100
Analyst Price Target
No estimates available

10

S

11

W

4

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Cocrystal Pharma Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Cocrystal Pharma Inc Stock Analysis

Cocrystal Pharma Inc stock analysis with key metrics, changes, and trends.

Cocrystal Pharma Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$17.98 M0.21%positive

Annual Net Profit rose 0.21% in the last year to $17.98 M. Its sector's average net profit growth for the last fiscal year was -32.42%.

Price to Earning Ratio-0.81-negative

Price to Earning Ratio is -0.81, which is negative.

Stock Price$1.485.71%positive

Stock Price rose 5.71% and outperformed its sector by 0.04% in the past year.

Quarterly Net profit$4.94 M18.58%negative

Quarterly Net profit fell 18.58% YoY to $4.94 M. Its sector's average net profit growth YoY for the quarter was -47.39%.

Debt to Equity Ratio0.07-positive

Debt to Equity Ratio of 0.07 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-54.54 %-54.54%negative

Return on Equity(ROE) for the last financial year was -54.54%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding6.59 %0.06%positive

Mutual Fund Holding increased by 0.06% in the last quarter to 6.59.

Promoter Share Holding8.24 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 8.24%.

Institutional Holding6.99 %-0.08%negative

Institutional Holding decreased by 0.08% in the last quarter to 6.99.

VIEW LESS


Loading data..

Cocrystal Pharma Inc - Company Profile

What does Cocrystal Pharma Inc do?

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma Inc Management structure

All Gross Remunerations are in USD
Mr. James J. Martin
Co-Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
627.2 K
2023
Gross Remuneration
Year
Dr. Sam Lee, PhD
President and Co-Chief Executive Officer
627.2 K
2023
Gross Remuneration
Year

Cocrystal Pharma Inc Board of directors

All Gross Remunerations are in USD
Dr. Roger D. Kornberg, PhD
Chairman of the Board
184.84 K
2023
Gross Remuneration
Year
Mr. Steven D. Rubin
Independent Director
113.51 K
2023
Gross Remuneration
Year
Dr. Phillip Frost, M.D.
Independent Director
84.12 K
2023
Gross Remuneration
Year
Dr. Anthony Japour, M.D.
Independent Director
79.97 K
2023
Gross Remuneration
Year
Mr. Fred Hassan
Independent Director
49.47 K
2023
Gross Remuneration
Year
Mr. Richard C. Pfenniger, Jr
Independent Director
44.23 K
2023
Gross Remuneration
Year

Cocrystal Pharma Inc FAQ

How is Cocrystal Pharma Inc today?
Cocrystal Pharma Inc today is trading in the green, and is up by 3.50% at 1.48.
Cocrystal Pharma Inc is currently trading up 3.50% on an intraday basis. In the past week the stock fell -5.13%. stock has been down -52.10% in the past quarter and rose 5.71% in the past year. You can view this in the overview section.